|
1.
|
|
8 p, 1.2 MB |
AXL - a new player in resistance to HER2 blockade
/
Adam-Artigues, Anna (INCLIVA Biomedical Research Institute) ;
Arenas, Enrique J (Centro de Investigación Biomédica en Red de Cáncer) ;
Arribas, Joaquín V (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Prat, Aleix (SOLTI Breast Cancer Research Group) ;
Cejalvo, Juan Miguel (Vall d'Hebron Institut d'Oncologia)
HER2 is a driver in solid tumors, mainly breast, oesophageal and gastric cancer, through activation of oncogenic signaling pathways such as PI3K or MAPK. HER2 overexpression associates with aggressive disease and poor prognosis. [...]
2023 -  10.1016/j.ctrv.2023.102639
Cancer Treatment Reviews, Vol. 121 (december 2023) , p. 102639
|
|
|
2.
|
|
19 p, 1.6 MB |
Strategies to design clinical studies to identify predictive biomarkers in cancer research
/
Perez-Gracia, Jose Luis (Clínica Universidad de Navarra) ;
Sanmamed, Miguel F. (Yale University School of Medicine) ;
Bosch, Ana (Lund University) ;
Patiño-Garcia, Ana (Clínica Universidad de Navarra) ;
Schalper, Kurt A. (Yale School of Medicine) ;
Segura, Victor (Universidad de Navarra) ;
Bellmunt, Joaquim (Dana-Farber Cancer Institute and Harvard Medical School) ;
Tabernero, Josep (Hospital Universitari Vall d'Hebron) ;
Sweeney, Christopher J. (Dana-Farber Cancer Institute and Harvard Medical School) ;
Choueiri, Toni K. (Dana-Farber Cancer Institute and Harvard Medical School) ;
Martín Jiménez, Miguel (Hospital Gregorio Marañón. Instituto de Investigación Sanitaria) ;
Fusco, Juan Pablo (Clínica Universidad de Navarra) ;
Rodriguez-Ruiz, Maria Esperanza (Universidad de Navarra) ;
Calvo, Alfonso (Universidad de Navarra) ;
Prior, Celia (Universidad de Navarra) ;
Paz-Ares, Luis (Hospital Universitario 12 de Octubre (Madrid)) ;
Pio, Ruben (Universidad de Navarra) ;
Gonzalez-Billalabeitia, Enrique (Universidad Católica San Antonio de Murcia) ;
Gonzalez Hernandez, Alvaro (Clínica Universidad de Navarra) ;
Páez, David (Institut d'Investigació Biomèdica Sant Pau) ;
Piulats, Jose María (Institut Català d'Oncologia) ;
Gurpide, Alfonso (Universidad de Navarra) ;
Andueza, Mapi (Clínica Universidad de Navarra) ;
de Velasco, Guillermo (Dana-Farber Cancer Institute and Harvard Medical School) ;
Pazo, Roberto (Hospital Universitario Miguel Servet (Saragossa)) ;
Grande, Enrique (Hospital Universitario Ramón y Cajal (Madrid)) ;
Nicolas, Pilar (Universidad del País Vasco) ;
Abad-Santos, Francisco (Instituto de Investigación Sanitaria la Princesa (IP)) ;
Garcia-Donas, Jesus (Centro Integral Oncológico HM Clara Campal) ;
Castellano, Daniel (Hospital Universitario 12 de Octubre (Madrid)) ;
Pajares, María J. (Universidad de Navarra) ;
Suárez, Cristina (Hospital Universitari Vall d'Hebron) ;
Colomer, Ramon (Hospital Universitario de la Princesa (Madrid)) ;
Montuenga, Luis M. (Universidad de Navarra) ;
Melero, Ignacio (Universidad de Navarra) ;
Universitat Autònoma de Barcelona
The discovery of reliable biomarkers to predict efficacy and toxicity of anticancer drugs remains one of the key challenges in cancer research. Despite its relevance, no efficient study designs to identify promising candidate biomarkers have been established. [...]
2017 - 10.1016/j.ctrv.2016.12.005
Cancer Treatment Reviews, Vol. 53 (january 2017) , p. 79-97
|
|
|
3.
|
|
8 p, 664.2 KB |
Exposure-response modeling of cabozantinib in patients with renal cell carcinoma : Implications for patient care
/
Castellano, Daniel (Hospital Universitario 12 de Octubre (Madrid)) ;
Maroto Rey, Pablo (Institut d'Investigació Biomèdica Sant Pau) ;
Benzaghou, Fawzi (Ipsen Pharma) ;
Taguieva, Naila (Ipsen Pharma) ;
Nguyen, Linh (Exelixis. Inc.) ;
Clary, Douglas O. (Exelixis. Inc.) ;
Jonasch, Eric W. (The University of Texas MD Anderson Cancer Center) ;
Universitat Autònoma de Barcelona
Cabozantinib is an oral tyrosine kinase inhibitor (TKI) approved for the treatment of patients with advanced renal cell carcinoma (RCC) at a dose of 60 mg/day. As with other TKIs, cabozantinib is associated with high interpatient variability in drug clearance and exposure that can significantly impact safety and tolerability across a patient population. [...]
2020 - 10.1016/j.ctrv.2020.102062
Cancer Treatment Reviews, Vol. 89 (september 2020) , p. 102062
|
|
|
4.
|
|
10 p, 3.2 MB |
Liquid biopsy after resection of pancreatic adenocarcinoma and its relation to oncological outcomes. Systematic review and meta-analysis
/
Vidal, Laura (Hospital Universitari Vall d'Hebron) ;
Pando, Elizabeth (Hospital Universitari Vall d'Hebron) ;
Blanco Cuso, Laia (Hospital Universitari Vall d'Hebron) ;
Fabregat-Franco, Carles (Hospital Universitari Vall d'Hebron) ;
Sierra, Alexandre (Hospital Universitari Vall d'Hebron) ;
Macarulla Mercadé, Teresa (Hospital Universitari Vall d'Hebron) ;
Balsells, Joaquim (Hospital Universitari Vall d'Hebron) ;
Charco, Ramon (Hospital Universitari Vall d'Hebron) ;
Vivancos, Ana (Hospital Universitari Vall d'Hebron) ;
Universitat Autònoma de Barcelona
It has been hypothesised that manipulation during surgery releases tumoral components into circulation. We investigate the effect of surgery on plasma-borne DNA biomarkers and the oncological outcomes in resectable pancreatic ductal adenocarcinoma (PDAC). [...]
2023 - 10.1016/j.ctrv.2023.102604
Cancer Treatment Reviews, Vol. 120 (2023) , p. 102604
|
|
|
5.
|
|
10 p, 1.2 MB |
SELNET clinical practice guidelines for soft tissue sarcoma and GIST
/
Blay, Jean-Yves (Léon Bérard Center (Lyon)) ;
Hindi, Nadia (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) ;
Bollard, Julien (Léon Bérard Center (Lyon)) ;
Aguiar Júnior, Samuel (A.C.Camargo Cancer Center (Brasil)) ;
Ángel, Martín Osvaldo (Instituto Alexander Fleming (Buenos Aires)) ;
Araya, Beatriz (Hospital Dr. R. A. Calderón Guardia (San José)) ;
Badilla-González, Ronald (Hospital Dr. Rafael Ángel Calderón Guardia (San José)) ;
Bernabeu, Daniel (Hospital Universitario La Paz (Madrid)) ;
Campos, Fernando (A.C.Camargo Cancer Center (Brasil)) ;
Caro-Sánchez, C.H.S. (Instituto Nacional de Cancerología (Tlalpan)) ;
Carvajal, B. (Fundación GIST México (Mexico)) ;
Carvajal Montoya, A. (Hospital Dr. Rafael Ángel Calderón Guardia (San José)) ;
Casavilca-Zambrano, Sandro (Instituto Nacional de Enfermedades Neoplásicas (Lima)) ;
Castro-Oliden, Victor (Instituto Nacional de Enfermedades Neoplásicas (Lima)) ;
Chacón, Matias (Instituto Alexander Fleming (Buenos Aires)) ;
Clara, Miguel (Instituto Nacional de Cancerología (Tlaplan)) ;
Collini, Paola (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà)) ;
Correa Genoroso, Raquel (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Costa, Felipe D. (A.C.Camargo Cancer Center (Brasil)) ;
Cuellar, M. (Fundación GIST México (Mexico)) ;
Dei Tos, Angelo (Treviso General Hospital Treviso (Padua)) ;
Dominguez Malagón, Hugo Ricardo (Instituto Nacional de Cancerología (Tlalpan)) ;
Donati, Davide Maria (IRCCS Istituto Ortopedico Rizzoli (Bologna)) ;
Dufresne, Armelle (Léon Bérard Center (Lyon)) ;
Eriksson, Mikael (Skane University Hospital (Lund)) ;
Farias-Loza, M. (Instituto Nacional de Enfermedades Neoplásicas (Lima)) ;
Fernandez, Piga (Fundación GIST (Xile)) ;
Frezza, Anna Maria (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà)) ;
Frisoni, Tommaso (IRCCS Istituto Ortopedico Rizzoli (Bologna)) ;
Garcia-Ortega, Dorian Yarih (Instituto Nacional de Cancerología (Tlalpan)) ;
Gelderblom, Hans J (Leiden University Medical Center (Leiden)) ;
Gouin, François (Léon Bérard Center (Lyon)) ;
Gómez-Mateo, María Carmen (Hospital Universitario Miguel Servet (Saragossa)) ;
Gronchi, Alessandro (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà)) ;
Haro-Varas, Juan (Instituto Nacional de Enfermedades Neoplásicas (Lima)) ;
Huanca, Lourdes (Instituto Nacional de Enfermedades Neoplásicas (Lima)) ;
Jimenez, Natalia (Hospital Dr. Rafael Ángel Calderón Guardia (San José)) ;
Karanian, Marie (Léon Bérard Center (Lyon)) ;
Kasper, Bernd (University of Heidelberg (Mannheim)) ;
Lopes David, B.B. (Fondazione IRCCS Istituto Nazionale dei Tumori) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
Lutter, Guido (Instituto Alexander Fleming (Buenos Aires)) ;
Martinez-Said, Héctor (Hospital Medica Sur (Mexico)) ;
Martinez-Tlahuel, Jorge Luis (Instituto Nacional de Cancerología (Tlalpan)) ;
Mello, Celso A. (A.C.Camargo Cancer Center (Brasil)) ;
Morales Pérez, José Manuel (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Moura, David S. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Nascimento, Antônio Geraldo (A.C.Camargo Cancer Center (Brasil)) ;
Ortiz-Cruz, Eduardo J. (Hospital Universitario La Paz (Madrid)) ;
Palmerini, Emanuela (IRCCS Istituto Ortopedico Rizzoli (Bologna)) ;
Patel, Shreyaskumar (University of Texas MD Anderson Cancer Center (Houston)) ;
Pfluger, Yanina (Instituto Alexander Fleming (Buenos Aires)) ;
Provenzano, Salvatore (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà)) ;
Righi, Alberto (IRCCS Istituto Ortopedico Rizzoli (Bologna)) ;
Rodriguez, Andrés (Instituto Alexander Fleming (Buenos Aires)) ;
Salas, Rodrigo (Fundación GIST México (Mexico)) ;
Santos, Telma G. (A.C.Camargo Cancer Center (Brasil)) ;
Scotlandi, Katia (IRCCS Istituto Ortopedico Rizzoli (Bologna)) ;
Soulé, Tomás (Instituto Alexander Fleming (Buenos Aires)) ;
Stacchiotti, Silvia (Fondazione IRCCS Istituto Nazionale dei Tumori (Milà)) ;
Valverde, Claudía María (Hospital Universitari Vall d'Hebron) ;
Waisberg, Federico Daniel (Instituto Alexander Fleming (Buenos Aires)) ;
Zamora Estrada, Esteban (Hospital Dr. Rafael Ángel Calderón Guardia (San José)) ;
Martín-Broto, Javier (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz)
2022 - 10.1016/j.ctrv.2021.102312
Cancer Treatment Reviews, Vol. 102 (january 2022) , p. 102312
|
|
|
6.
|
|
12 p, 3.1 MB |
Biological and clinical perspectives of the actionable gene fusions and amplifications involving tyrosine kinase receptors in lung cancer
/
Saigí, Maria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Carcereny, Enric (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Cucurull, Marc (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Domènech, Marta (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Hernández, Ainhoa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Martinez-Cardús, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Pros, Eva (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sanchez-Cespedes, Montse (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Identifying molecular oncogenic drivers is crucial for precision oncology. Genetic rearrangements, including gene fusions and gene amplification, involving and activating receptor tyrosine kinases (RTKs) are recurrent in solid tumors, particularly in non-small cell lung cancer. [...]
2022 - 10.1016/j.ctrv.2022.102430
Cancer Treatment Reviews, Vol. 109 (september 2022) , p. 102430
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
